| Literature DB >> 35646184 |
Leyla Jafari1, Kyumars Safinejad2, Mahboobeh Nasiri1, Mansour Heidari3, Massoud Houshmand4.
Abstract
Due to progress in infertility etiology, several genetic bases of infertility are revealed today. This study aimed to investigate the distribution of mutations in the CFTR gene, M470V polymorphism, and IVS8 poly T. Furthermore, we aimed to examine the hotspot exons (4, 7, 9, 10, 11, 20, and 21 exons) to find a new mutation in cystic fibrosis transmembrane conductance regulator (CFTR) gene among infertile Iranian men very severe oligozoospermia (<1 million sperm/mL ejaculate fluid). In the present case-control study, 200 very severe oligozoospermia (20-60s) and 200 fertile men (18-65s) were registered. Five common CFTR mutations were genotyped using the ARMS-PCR technique. The M470V polymorphism was checked out by real-time PCR, and poly T and exons were sequenced. The F508del was the most common (4.5%) CFTR gene mutation; G542X and W1282X were detected with 1.5% and 1%, respectively. N1303K and R117H were detected in 0.5% of cases. F508del was seen as a heterozygous compound with G542X in one patient and with W1282X in the other patient. Also, in the case of M470V polymorphism, there are differences between the case and control groups (p=0.013). Poly T assay showed statistical differences in some genotypes. The study showed no new mutation in the exons mentioned above. Our results shed light on the genetic basis of men with very severe oligozoospermia in the Iranian population, which will support therapy decisions among infertile men. ©2022 JOURNAL of MEDICINE and LIFE.Entities:
Keywords: ACECR – Academic Center for Education, Culture, and Research; ARMA – Amplification-refractory mutation system; CBAVD – Congenital bilateral absence of the vas deferens; CF – Cystic fibrosis; CFTR gene; EDTA – Ethylenediaminetetraacetic acid; ICSI – Intracytoplasmic sperm injection; IVS8 poly T; M470V polymorphism; N1303K; R117H; SSCP – Single strand conformational polymorphism; very severe oligozoospermia
Mesh:
Substances:
Year: 2022 PMID: 35646184 PMCID: PMC9126445 DOI: 10.25122/jml-2021-0261
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
Figure 1.Study flowchart.
Primers sequences and the amplified product sizes.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| GACTTCACTTCTAATGATGATTATGGGAG | 160 | Exon 4 | TCACATATGGTATGACCCTC | 438 |
|
| GACTTCACTTCTAATGATGATTATGGGAG | 256 257 | Exon 7 | AGACCATGCTCAGATCTTCCAT | 410 |
|
| CACATATGGTATGACCCTCTATATAAACTC | 237 | Exon 9 | CATAAAACAAGCATCTATTG | 322 |
|
| CTCAATTTCTTTATTCTAAAGACATTGG | 328 | Exon 10 | GCAGAGTACCTGAAACAGGA | 491 |
|
| CCCATCACTTTTACCTTATAGGTGGGCCTC | 178 | Exon 11 | CAACTGTGGTTAAAGCAATAGTGT | 425 |
|
| CTTCTGCTTAGGATGATAATTGG | Probe for | Exon 20 | GGTCAGGATTGAAAGTGTGCA | 471 |
|
| 5T forward: GTGTGTGTGTGTGTGTGTTGTT | - | Exon 21 | AATGTTCACAAGGGACTCCA | 477 |
PCR conditions to amplify ΔF508.
|
|
|
|
|
|---|---|---|---|
|
| 95 | 3 min | 1 |
|
| 93 | 35 sec | 35 |
|
| 53 | 40 sec | |
|
| 72 | 35 sec | |
|
| 72 | 5 min | 1 |
PCR conditions to amplify IVS8.
|
|
|
|
|
|---|---|---|---|
|
| 95 | 30 sec | 1 |
|
| 95 | 5 sec | 35 |
|
| 57 | 15 sec | |
|
| 72 | 34 sec | |
|
| 72 | 5 min | 1 |
|
| 95 | 30 sec | 1 |
|
| 64 | 40 sec | 35 |
|
| 70 | 90 sec | |
|
| 72 | 180 sec | 1 |
PCR conditions to amplify Exons 4, 9 and 10.
|
|
|
|
|
|---|---|---|---|
|
| 95 | 3 min | 1 |
|
| 95 | 30 sec | 35 |
|
| 56 | 40 sec | |
|
| 72 | 30 sec | |
|
| 72 | 5 min | 1 |
CFTR gene mutations distribution.
|
|
|
|
|
|---|---|---|---|
|
| p.Phe508del | c.1521_1523delCTT | 9 (4.5%) |
|
| p.Gly542X | c.1624G>T | 3 (1.5%) |
|
| p.Try1282X | c.3846G>A | 2 (1%) |
|
| p.Asn1303Lys | c.3909C>G | 1 (0.5%) |
|
| p.Arg117His | c.350G>A | 1 (0.5%) |
Figure 2.CFTR gene mutations genotyping on 2% agarose gel electrophoresis; 1. W1282X normal (178bp), 2. W1282X heterozygote (178bp) 3. G542X normal (257bp), 4. G542X heterozygote (256bp), 5. R117H normal (237 bp), 6. R117H heterozygous (236 bp).
M470V polymorphism prevalence in case and control.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
| M470V | p.Val470Met | c.1408G>A | 85 (43%) | 79 (39%) | 36 (18%) |
|
| M470V | p.Val470Met | c.1408G>A | 114 (57%) | 64 (32%) | 22 (11%) |
Figure 4.Sequencing of M470V in homozygote and heterozygote status.
Figure 5.HpaI digestion results on ethidium-bromide–stained polyacrylamide gel. 1 &9 Marker 100bp. 2 &10 Uncut product, 3 &11 5T5T, 4 &12 5T7T, 5 &13 5T9T, 6 &14 7T7T, 7 &15 7T9T and 8 &16 9T9T.
Poly T genotype distribution in case and control.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
| 22 (11%) | 66 (33%) | 5 (2.5%) | 104 (52%) | 2 (1%) | 1 (0.5%) |
|
| 4 (2%) | 16 (8%) | 2 (1%) | 177 (88.5) | 1 (0.5%) | 0 (0%) |
|
| <0.01 | <0.01 | 0.069 | <0.01 | 0.169 | 0.073 |
Figure 6.PCR product of hotspot exons. 1-3 exon10 (491bp), 4-6 exon 11(425bp), 7 and 9-10 exon 9 (322bp), 11-12 exon 4 (438bp), lane 8 marker 50bp.
PCR conditions to amplify G542X, R117H, N1303K and W1282X.
|
|
|
|
|
|---|---|---|---|
|
| 95 | 5 min | 1 |
|
| 95 | 30 sec | 35 |
|
| 50 | 60 sec | |
|
| 72 | 60 sec | |
|
| 72 | 10 min | 1 |
PCR conditions to amplify M470V.
|
|
|
|
|
|---|---|---|---|
|
| 95 | 30 sec | 1 |
|
| 95 | 5 sec | 50 |
|
| 57 | 15 sec | |
|
| 72 | 34 sec | |
|
| 72 | 5 min | 1 |
PCR condition to amplify Exons 7, 11, 20 and 21.
|
|
|
|
|
|---|---|---|---|
|
| 95 | 5 min | 1 |
|
| 95 | 30 sec | 35 |
|
| 52 | 60 sec | |
|
| 72 | 60 sec | |
|
| 72 | 10 min | 1 |
The simultaneous occurrence of genetic changes in Yq or CFTR and AR genes.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| √ | √ | 1 | 0.5 | ||
| √ | √ | 1 | 0.5 |